Skip to content
Syntara
A clinical‐stage drug development company primarily focused on blood related cancers.
SyntaraSyntara
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact
  • Welcome
  • People
    • Board
    • Management
  • Pipeline
  • Clinical Trials
  • Investors
    • Investors home page
    • ASX Announcements
    • Quarterly Reports
    • Annual & Half-Yearly Reports
    • Investor Presentations
    • Media
    • Conference Posters
    • Analyst Reports
    • Shareholders
    • Shareholder Services
    • Corporate Governance
  • Contact

Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment

You are here:
  1. Home
  2. Media
  3. Syntara Expands Safety and Tolerability…

Share

Linkedin
Ask me anything

Submit

Your question will be sent privately to Syntara Therapeutics. The company may choose to make this question public.

Highlights

Additional data from SNT-4728 Phase 2 study shows significant improvement in clinician assessed motor signs

Read More »

Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment

Read More »

Syntara expands SNT-9465 skin scarring study

Read More »

Subscribe to our news

Subscribe

Syntara is a clinical stage drug development company focused on haematological malignancies.

Linkedin

ABN 75 082 811 630

Quick Links
  • Pipeline
  • Investors
  • Highlights
  • Pipeline
  • Investors
  • Highlights
Subscribe to our News
Get In Touch
  • Locked Bag 5015 
    Frenchs Forest 
NSW 2086
    AUSTRALIA
  • info@syntaratx.com.au 
  • +61 2 8760 1480

2026 © Syntara Limited.

Legal

Go to Top